Study on the effect of a new anti-ulcer agent, ecabet sodium, on the dual therapy for eradication of Helicobacter pylori in randomized patients

Kagaya, Hidetoshi; Kato, Mototsugu; Kobayashi, T; Ishizuka, Jun; Nishikawa, Kaori; Sukegawa, Makoto; Takeda, Hiroshi; Sugiyama, T.; Asaka, M

doi:10.1016/s0016-5085(98)80666-5

Cited by 5 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Six kinds of mucosal defensive agents, rebamipide, ecabet sodium, polaprezinc, plaunotol, sofalcon, sucralfate, and maalox dry suspension granule, were included in the selected studies. The ITT based eradication rates as well as the relative risks, comparing regimens with mucosal defensive agents to those without, in the selected studies were summarized in Table 1 for dual therapy regimens and in Table 2 for triple therapy regimens 32 –48 …”

Section: Resultsmentioning

confidence: 99%

“…Many studies which discuss the efficacy of mucosal defensive agents in eradicating H. pylori or serve as review articles on the subject have been reported 32 –48 . However, there is no article available in which each result is systematically combined and surveyed using statistical methods, and so we assessed the efficacy of mucosal defensive agents when used in combination with ordinary dual or triple therapies using statistical analysis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Do mucosal defensive agents improve the cure rate when used with dual or triple therapy regimens for eradicating Helicobacter pylori infection?

Hojo

Miwa

Kikuchi

et al. 2000

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Background: Some of mucosal defensive agents have anti‐Helicobacter pylori activities. However, their effectiveness in eradicating H. pylori infection has not been evaluated. Aim: To assess the additive effect of mucosal defensive agents in eradication regimens using statistical analysis. Methods: Pertinent studies were retrieved using the Medline and the Igaku–chuo–zasshi databases in Japan, reference and congress abstract lists. Studies in which regimens consisted of dual or triple therapy with mucosal defensive agents and without them, were selected from the retrieved studies. Eradication rates were extracted from studies according to intention‐to‐treat analysis. We evaluated the efficacies of mucosal defensive agents by pooled relative risk of eradication rates and its 95% confidence intervals (95% CI), which were calculated by Mantel–Haenszel method. Heterogeneity among the studies in treatment effect was evaluated by a χ2‐test. Results: In dual therapy regimens, mucosal defensive agents demonstrated significant additive effects (pooled relative risk 1.41; 95% CI: 1.24–1.61). In triple therapy regimens, these agents did not provide significant additive effect. The clinical usefulness of specific agents could not be established, when each agent was analysed independently. Conclusions: Mucosal defensive agents improve the cure rate when used with existing dual therapy regimens for eradicating H. pylori infection.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Do mucosal defensive agents improve the cure rate when used with dual or triple therapy regimens for eradicating Helicobacter pylori infection?

Hojo

Miwa

Kikuchi

et al. 2000

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…A total of 73 studies (57 papers and 16 abstracts) were included in this systematic overview. 10–82 Of those, 60 were randomized controlled trials. The study design was unclear or unstated in 13 reports.…”

Section: Resultsmentioning

confidence: 99%

Pooled analysis of Helicobacter pylori eradication regimes in Asia

Wang

Wong

Lam

2000

J of Gastro and Hepatol

View full text Add to dashboard Cite

Proton pump inhibitor-based triple therapy with either clarithromycin, amoxycillin or metronidazole was one of the most commonly used and effective anti-H. pylori triple therapy regimens in Asia. The classical triple therapy with a bismuth, tetracycline and metronidazole combination has a similar efficacy. The results of anti-H. pylori treatment in Asia are not different from those in Western countries.

show abstract

“…(1) Anti-bacterial effects. Triple therapy with amoxicillin, ecabet and a proton pump inhibitor effectively eradicated H. pylori [4,5]. Ecabet prevents the survival of H. pylori in the stomach via inhibition of essential urease activity [6,7], and inhibits the adhesion of H. pylori to gastric epithelia [8].…”

Section: Introductionmentioning

confidence: 99%

Mucosal protective effects of ecabet sodium: pepsin inhibition and interaction with mucus

Pearson

Roberts

2001

Clinical Science

View full text Add to dashboard Cite

Pepsin, acid and Helicobacter pylori are major factors in the pathophysiology of peptic ulcer disease and reflux oesophagitis. Ecabet sodium reduces the survival of H. pylori in the stomach and inhibits pepsin activity in the gastric juice of experimental animals. Here we have investigated the effects of ecabet sodium on some of the factors involved in the dynamics of the mucosal barrier, i.e. pepsins and mucins. This study used gastric juice obtained from 12 non-symptomatic volunteers and nine patients with reflux oesophagitis. Ecabet sodium significantly inhibited pepsin activity in human gastric juice, with a maximum inhibition of 78%. Pepsin 1, the ulcer-associated pepsin, was inhibited to the greatest extent. The ability of gastric juice to digest mucin was significantly inhibited by ecabet. As with gastric juice proteolytic activity, the inhibitory effect of ecabet on mucolysis was greater in gastric juice from patients with reflux oesophagitis than in that from controls. Ecabet sodium showed a positive interaction with gastric mucin, as assessed by an increase in viscosity. Thus ecabet sodium may reduce the aggressive potential of gastric juice towards the mucosa, which may be relevant in the treatment of reflux oesophagitis and peptic ulcer disease. In addition, it may strengthen the mucus barrier in peptic ulcer disease and gastritis.

show abstract

Study on the effect of a new anti-ulcer agent, ecabet sodium, on the dual therapy for eradication of Helicobacter pylori in randomized patients

Cited by 5 publications

References 0 publications

Do mucosal defensive agents improve the cure rate when used with dual or triple therapy regimens for eradicating Helicobacter pylori infection?

Do mucosal defensive agents improve the cure rate when used with dual or triple therapy regimens for eradicating Helicobacter pylori infection?

Pooled analysis of Helicobacter pylori eradication regimes in Asia

Mucosal protective effects of ecabet sodium: pepsin inhibition and interaction with mucus

Contact Info

Product

Resources

About